DURECT Corporation

378 articles with DURECT Corporation

• DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

  3/9/2023

  DURECT Corporation announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15th, 2023.

• DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update

  3/7/2023

  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a corporate update.

• DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

  2/28/2023

  DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023.

• DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants

  2/3/2023

  DURECT Corporation announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of an aggregate of 1,700,000 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase 300,000 shares of common stock, and accompanying warrants to purchase up to 2,000,000 shares of common stock in a registered direct offering.

• DURECT Announces 1-for-10 Reverse Stock Split

  11/28/2022

  DURECT Corporation announced that DURECT's board of directors determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022.

• DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs

  11/2/2022

  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update.

• DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2

  10/26/2022

  DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022.

• DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial

  10/6/2022

  DURECT Corporation today announced the enrollment of more than 200 of the planned 300 patients in its Phase 2b AHFIRM trial.

• Innocoll and DURECT Announce U.S. launch of POSIMIR®

  9/26/2022

  Innocoll, Inc. Limited, a commercial-stage biotechnology  company and portfolio business of Gurnet Point Capital, and DURECT Corporation (Nasdaq: DRRX) today announced the recent commercial launch of POSIMIR® (bupivacaine solution) in the United States.

• DURECT Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  DURECT Corporation announced that Dr. James E. Brown, President and CEO will be presenting virtually at the H.C. Wainwright 24th annual Global Investment Conference.

• DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs

  8/4/2022

  DURECT Corporation announced financial results for the three months ended June 30, 2022 and provided a corporate update.

• DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4

  7/27/2022

  DURECT Corporation announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Thursday, August 4, 2022.

• 

  Movers & Shakers: Adagio, Harpoon, Aravive, Nitrase and More

  7/8/2022

  Adagio, Aravive, PolyPid, Harpoon, Durect, Nitrase, Kallyope, TScan and many more made major leadership decisions this week.

• DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

  7/5/2022

  DURECT Corporation  (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer.

• DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

  5/18/2022

  DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown , President and CEO, Dr. Norman Sussman , Chief Medical Officer, and Dr. WeiQi Lin , Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce , Managing Director of Equity Research at H.C. Wainwright. 

• DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs

  5/4/2022

  DURECT Corporation announced financial results for the three months ended March 31, 2022 and provided a corporate update.

• DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4

  4/27/2022

  DURECT Corporation announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Wednesday, May 4, 2022.

• DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit

  3/23/2022

  DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown , President and CEO, will be participating in a panel discussion at the Cantor Virtual Rare Orphan Disease Summit

• DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

  3/9/2022

  DURECT Corporation announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr. Norman Sussman, Chief Medical Officer, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022.

• DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs

  3/7/2022

  DURECT Corporation announced financial results for the three months and year ended December 31, 2021 and provided a corporate update.